Zacks Research Upgrades TG Therapeutics (NASDAQ:TGTX) to “Strong-Buy”

Posted by Geri Gentry on Nov 6th, 2026

TG Therapeutics (NASDAQ:TGTX – Get Free Report) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Wednesday, Zacks reports.

TGTX has been the topic of several other research reports. Weiss Ratings downgraded shares of TG Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, October 23rd. JPMorgan Chase & Co. raised their price target on shares of TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. B. Riley Financial lifted their price objective on shares of TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a research note on Monday, July 27th. Bank of America boosted their price objective on shares of TG Therapeutics from $17.00 to $20.00 and gave the company an “underperform” rating in a report on Tuesday, July 7th. Finally, HC Wainwright reissued a “buy” rating and set a $78.00 price objective on shares of TG Therapeutics in a report on Tuesday, September 1st. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $63.00.

Get Our Latest Stock Analysis on TGTX

TG Therapeutics Price Performance

Shares of TGTX stock opened at $57.98 on Wednesday. TG Therapeutics has a fifty-two week low of $26.76 and a fifty-two week high of $63.60. The firm has a market capitalization of $8.87 billion, a price-to-earnings ratio of 21.16, a PEG ratio of 2.60 and a beta of 1.89. The company has a debt-to-equity ratio of 1.23, a quick ratio of 3.72 and a current ratio of 4.27. The stock’s 50-day simple moving average is $55.72 and its 200-day simple moving average is $44.36.

TG Therapeutics (NASDAQ:TGTX – Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.26). The company had revenue of $240.34 million for the quarter, compared to analyst estimates of $229.77 million. TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The business’s revenue was up 70.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.17 EPS. As a group, equities analysts forecast that TG Therapeutics will post 0.92 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Laurence Charney sold 5,000 shares of TG Therapeutics stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $54.96, for a total transaction of $274,800.00. Following the completion of the sale, the director owned 168,640 shares of the company’s stock, valued at $9,268,454.40. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 8.87% of the stock is currently owned by insiders.

Hedge Funds Weigh In On TG Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Fifth Third Bancorp boosted its stake in shares of TG Therapeutics by 181.1% in the third quarter. Fifth Third Bancorp now owns 171,291 shares of the biopharmaceutical company’s stock worth $9,555,000 after buying an additional 110,365 shares during the last quarter. Maryland State Retirement & Pension System grew its holdings in TG Therapeutics by 65.2% during the third quarter. Maryland State Retirement & Pension System now owns 31,673 shares of the biopharmaceutical company’s stock worth $1,767,000 after acquiring an additional 12,503 shares during the period. Jacobi Capital Management LLC acquired a new stake in TG Therapeutics during the third quarter worth about $57,000. Illinois Municipal Retirement Fund grew its holdings in TG Therapeutics by 15.1% during the third quarter. Illinois Municipal Retirement Fund now owns 67,221 shares of the biopharmaceutical company’s stock worth $3,750,000 after acquiring an additional 8,824 shares during the period. Finally, Lido Advisors LLC raised its position in TG Therapeutics by 6.8% during the third quarter. Lido Advisors LLC now owns 20,613 shares of the biopharmaceutical company’s stock valued at $1,150,000 after acquiring an additional 1,308 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

About TG Therapeutics

(Get Free Report)

TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering medicines for B-cell diseases, including multiple sclerosis and certain blood cancers. The company’s research and development programs are centered on therapies that target B cells and the immune system.

TG Therapeutics’ primary marketed product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved in the United States for the treatment of relapsing forms of multiple sclerosis in adults.